These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 12675208)
1. Peginterferon alfa-2a (40KD): a potent long-acting form of interferon alfa-2a for the treatment of hepatitis C. Modi MW; Lamb MW; Shiomi M Adv Exp Med Biol; 2003; 519():59-67. PubMed ID: 12675208 [No Abstract] [Full Text] [Related]
2. Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference? Sierra F J Hepatol; 2007 Feb; 46(2):349; author reply 349-50. PubMed ID: 17161495 [No Abstract] [Full Text] [Related]
3. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Chalasani N; Manzarbeitia C; Ferenci P; Vogel W; Fontana RJ; Voigt M; Riely C; Martin P; Teperman L; Jiao J; Lopez-Talavera JC; Hepatology; 2005 Feb; 41(2):289-98. PubMed ID: 15660392 [TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a in patients with chronic hepatitis C. Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715 [TBL] [Abstract][Full Text] [Related]
6. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C. Ferenci P Int J Clin Pract; 2003 Sep; 57(7):610-5. PubMed ID: 14529063 [TBL] [Abstract][Full Text] [Related]
7. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS; Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661 [TBL] [Abstract][Full Text] [Related]
8. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716 [TBL] [Abstract][Full Text] [Related]
9. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553 [TBL] [Abstract][Full Text] [Related]
11. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT; N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351 [TBL] [Abstract][Full Text] [Related]
12. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N; N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917 [TBL] [Abstract][Full Text] [Related]
13. Acute rejection of non-functional allograft in kidney transplant recipients with hepatitis C treated with peginterferon-alpha 2a. Sperl J; Petrasek J; Spicak J; Viklicky O J Hepatol; 2008 Sep; 49(3):461-2; author reply 462-3. PubMed ID: 18644649 [No Abstract] [Full Text] [Related]
14. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Forestier N; Reesink HW; Weegink CJ; McNair L; Kieffer TL; Chu HM; Purdy S; Jansen PL; Zeuzem S Hepatology; 2007 Sep; 46(3):640-8. PubMed ID: 17879366 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C treatment, HAART and side effects. TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865 [No Abstract] [Full Text] [Related]
16. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737 [TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N; N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578 [TBL] [Abstract][Full Text] [Related]
18. New advances in hepatitis C therapy. Proj Inf Perspect; 2000 Aug; (30):18-9. PubMed ID: 12171011 [TBL] [Abstract][Full Text] [Related]
19. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6. Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414 [No Abstract] [Full Text] [Related]
20. Reversible decompensated liver disease as a possible complication of pegylated-interferon alfa 2b and ribavirin for recurrent hepatitis C. Mukherjee S J Gastroenterol Hepatol; 2004 Jun; 19(6):723-4. PubMed ID: 15151639 [No Abstract] [Full Text] [Related] [Next] [New Search]